Storia in 3 fonti

First-in-Class Drug for ADHD Wins FDA Approval

Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older

Raccontata da

morningstar.com

medpagetoday.com

fiercepharma.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo15 h fa

First-in-Class Drug for ADHD Wins FDA Approval

Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older

originale

morningstar.com3 g fa

Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of…

Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older

Leggi questa versione → originale

Timeline cronologica

sabato 25 luglio 2026·morningstar.com
Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder…
Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients…
lunedì 27 luglio 2026·medpagetoday.com
First-in-Class Drug for ADHD Wins FDA Approval
Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older

First-in-Class Drug for ADHD Wins FDA Approval

Confronto fonti

First-in-Class Drug for ADHD Wins FDA Approval

Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of…

Timeline cronologica

Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder…

First-in-Class Drug for ADHD Wins FDA Approval

FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’

FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’